Abstract
Cardiovascular (CV) manifestations of COVID-19 infection carry significant morbidity and mortality. Current risk prediction for CV complications in COVID-19 is limited and existing approaches fail to account for the dynamic course of the disease. Here, we develop and validate the COVID-HEART predictor, a novel continuously-updating risk prediction technology to forecast CV complications in hospitalized patients with COVID-19. The risk predictor is trained and tested with retrospective registry data from 2178 patients to predict two outcomes: cardiac arrest and imaging-confirmed thromboembolic events. In repeating model validation many times, we show that it predicts cardiac arrest with an average median early warning time of 18 hours (IQR: 13-20 hours) and an AUROC of 0.92 (95% CI: 0.91-0.92), and thromboembolic events with a median early warning time of 72 hours (IQR: 12-204 hours) and an AUROC of 0.70 (95% CI: 0.67-0.73). The COVID-HEART predictor is anticipated to provide tangible clinical decision support in triaging patients and optimizing resource utilization, with its clinical utility potentially extending well beyond COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a RAPID grant (2029603) from the National Science Foundation to N.A.T., a grant from the Lowenstein Foundation to N.A.T., and a National Science Foundation Graduate Research Fellowship (DGE-1746891) to J.S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Johns Hopkins University Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Nested cross validation was added to provide a more accurate characterization of the COVID-HEART predictor's performance, including 95% confidence intervals for all cross-validation and test results. The feature space for prediction of thromboembolic events was significantly restricted in response to feedback regarding the number of events in the development cohort; results and figures were updated accordingly.
Data Availability
The authors declare that all data supporting the findings of this study are available within the paper and its supplementary information. The clinical data was all extracted from the JH-CROWN registry. Clinical data is available upon request at the following web address: https://ictr.johnshopkins.edu/coronavirus/jh-crown/. IRB approval is required to gain access to protected health information.
